These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24165884)

  • 21. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
    Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
    Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.
    Bosilkovska M; Samer CF; Déglon J; Rebsamen M; Staub C; Dayer P; Walder B; Desmeules JA; Daali Y
    Clin Pharmacol Ther; 2014 Sep; 96(3):349-59. PubMed ID: 24722393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study.
    Desch M; Schlecker C; Hohl K; Liesenfeld KH; Chan T; Müller F; Wunderlich G; Keller S; Ishiguro N; Wind S
    J Clin Psychopharmacol; 2023 Mar-Apr 01; 43(2):113-121. PubMed ID: 36700734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats.
    Uchida S; Tanaka S; Namiki N
    Biopharm Drug Dispos; 2014 May; 35(4):228-36. PubMed ID: 24395703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.
    Ryu JY; Song IS; Sunwoo YE; Shon JH; Liu KH; Cha IJ; Shin JG
    Clin Pharmacol Ther; 2007 Nov; 82(5):531-40. PubMed ID: 17392720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a six-probe cocktail (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam, and digoxin) approach to estimate hepatic drug detoxification capability and dosage requirements after a single oral dosing in healthy Chinese volunteers.
    Koo SH; Soon GH; Pruvost A; Benech H; Ang TL; Lee EJD; Ang DSW
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Jul; 395(7):815-826. PubMed ID: 35394133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
    Toda A; Uehara S; Inoue T; Utoh M; Kusama T; Shimizu M; Uno Y; Mogi M; Sasaki E; Yamazaki H
    Xenobiotica; 2018 Jul; 48(7):720-726. PubMed ID: 28686070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
    Dai X; Karol MD; Hitron M; Hard ML; Goulet MT; McLaughlin CF; Brantley SJ
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):824-839. PubMed ID: 34107166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
    Schöller-Gyüre M; Boffito M; Pozniak AL; Leemans R; Kakuda TN; Woodfall B; Vyncke V; Peeters M; Vandermeulen K; Hoetelmans RM
    Pharmacotherapy; 2008 Oct; 28(10):1215-22. PubMed ID: 18823217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; De Smedt G; Vanaken H; Bouche MP; Peeters M; Woodfall B; Hoetelmans RM
    Br J Clin Pharmacol; 2008 Oct; 66(4):508-16. PubMed ID: 18492125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.
    Snyder BD; Rowland A; Polasek TM; Miners JO; Doogue MP
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1115-22. PubMed ID: 25028073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
    Kakuda TN; Schöller-Gyüre M; De Smedt G; Beets G; Aharchi F; Peeters MP; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    HIV Med; 2009 Mar; 10(3):173-81. PubMed ID: 19207601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
    Flaherty KT; Lathia C; Frye RF; Schuchter L; Redlinger M; Rosen M; O'Dwyer PJ
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1111-8. PubMed ID: 21350850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities.
    Kirby B; Kharasch ED; Thummel KT; Narang VS; Hoffer CJ; Unadkat JD
    J Clin Pharmacol; 2006 Nov; 46(11):1313-9. PubMed ID: 17050796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
    Kakuda TN; Schöller-Gyüre M; Workman C; Arasteh K; Pozniak AL; De Smedt G; Beets G; Peeters M; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    Antivir Ther; 2008; 13(5):655-61. PubMed ID: 18771049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of commercial Rhodiola rosea on CYP enzyme activity in humans.
    Thu OK; Spigset O; Nilsen OG; Hellum B
    Eur J Clin Pharmacol; 2016 Mar; 72(3):295-300. PubMed ID: 26613955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
    Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
    Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels.
    Treijtel N; Collins C; van Bruijnsvoort M; Fuhr R; Ernault E; Gangaram-Panday S; Passier P
    Clin Pharmacol Drug Dev; 2019 May; 8(4):529-540. PubMed ID: 30730615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.
    Zhu Y; Xu Y; Zhuang Y; Piantone A; Shu C; Chen D; Zhou H; Xu Z; Sharma A
    Clin Transl Sci; 2020 Nov; 13(6):1217-1226. PubMed ID: 32407591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.